Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer
about
A high-content image-based method for quantitatively studying context-dependent cell population dynamicsParametric model of combination therapy for Non-Hodgkin LymphomaLeveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid TumorsProgress Towards Computational 3-D Multicellular Systems Biology.Evolution of acquired resistance to anti-cancer therapy.Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations.ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.Combination erlotinib-cisplatin and Atg3-mediated autophagy in erlotinib resistant lung cancer.Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR responseThe Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells.Diverse array-designed modes of combination therapies in Fangjiomics.Epigenetic changes mediated by polycomb repressive complex 2 and E2a are associated with drug resistance in a mouse model of lymphoma.Cross-talk between AMPK and EGFR dependent Signaling in Non-Small Cell Lung Cancer.Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population.Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathwayHotspot oncomutations: implications for personalized cancer treatment.Limiting the development of anti-cancer drug resistance in a spatial model of micrometastasesHomeostasis Back and Forth: An Ecoevolutionary Perspective of Cancer.Dual transcript and protein quantification in a massive single cell array.Unforeseen clonal evolution of tumor cell population in recurrent and metastatic dermatofibrosarcoma protuberans.Pharmacokinetics and Drug Interactions Determine Optimum Combination Strategies in Computational Models of Cancer Evolution.Computer simulations of the signalling network in FLT3 +-acute myeloid leukaemia - indications for an optimal dosage of inhibitors against FLT3 and CDK6.The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancer.
P2860
Q27329172-01A45A71-802C-476B-B0DE-0179092622DAQ28484381-64B33D7E-D462-4A80-8B20-E151BD3F2E5CQ28553729-2732189A-0666-4544-A2EC-2761E04D7E51Q30490175-ADACD64B-D3E2-440F-BFAD-CFA2D1B3A3EEQ33758382-478EC3C9-5187-4E1B-9275-8CA2C06444CEQ34066159-CD3DE3B7-7807-4823-A6F3-5E34605D0CBEQ34431889-42EC194D-83CE-4A43-9FD0-E74D5A011AC2Q34465240-98F947B3-0FC7-448F-B36A-CB70A0A4D14DQ35810693-5B19A53F-B5E8-4131-AE58-D0790341E983Q35857502-A22BA42D-EEA5-44AF-B687-9ED41566CBE5Q36123974-C8CB7077-E056-4FD6-9C8A-AB0343DD84A2Q36871785-A98AF7B4-545E-4CD6-A910-89E077925231Q36985909-E5FEDAF0-25D3-4BFE-9A59-6C190D9F6558Q37093554-044165A6-437D-4DE6-86B8-3C124DF61E25Q37715457-1057F4CB-9ECC-48E4-866D-307B5D84A119Q38030603-34EFA4CC-04DC-419C-A141-7A9878F3CF3CQ38738084-D1E11E77-AECD-49FC-BAA9-969E7CF5B16DQ38910371-58E25B13-1CEA-40DF-B078-06138A7890A6Q42242168-B5083189-AE69-4404-9A0D-650833873D43Q42370242-23197292-FFA9-461C-A84B-E1D19ECAAD7BQ48786945-B1F13322-9BFF-4D90-BCCB-8E9255E699F9Q54114106-FB2C9B4E-6177-4199-87FF-ED506F74F361Q54339322-74CCC54C-F6DE-43BF-9031-FA0792AB041F
P2860
Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Evolutionary modeling of combi ...... in non-small cell lung cancer
@ast
Evolutionary modeling of combi ...... in non-small cell lung cancer
@en
type
label
Evolutionary modeling of combi ...... in non-small cell lung cancer
@ast
Evolutionary modeling of combi ...... in non-small cell lung cancer
@en
prefLabel
Evolutionary modeling of combi ...... in non-small cell lung cancer
@ast
Evolutionary modeling of combi ...... in non-small cell lung cancer
@en
P2093
P2860
P356
P1476
Evolutionary modeling of combi ...... in non-small cell lung cancer
@en
P2093
David B Agus
Franziska Michor
Jasmine Foo
Kevin Leder
Nathan C Choi
Parag Mallick
Shannon M Mumenthaler
P2860
P304
P356
10.1021/MP200270V
P407
P50
P577
2011-10-25T00:00:00Z